

Contact: Richard C. Auletta
rca@auletta.com

Dolores Naney
dnaney@auletta.com

FOR IMMEDIATE RELEASE

FERGHANA PARTNERS GROUP
COMPLETES DIVESTITURE ASSIGNMENT
FOR AVENTIS

Schering AG Acquires Refludan® from Aventis S.A.

NEW YORK, NEW YORK, October 2, 2001 – The Federal Trade Commission (FTC) and the European Commission appointed Ferghana Partners Group to act as Divestiture Trustee for the sale of Refludan by Aventis S.A. in August 2000. After European and U.S. regulatory approvals last week, the deal was closed today with Schering AG of Berlin, Germany acquiring the worldwide rights to Refludan from Aventis S.A.

Following the merger between Hoechst AG and Rhone-Poulenc, the company, renamed Aventis S.A., was required to divest itself of Refludan, which is the leading treatment of thrombosis associated with Heparin Induced Thrombocytopenia (HIT), a rare, yet potentially life threatening response to heparin therapy. Ferghana Partners was appointed by both the FTC and the European Commission to serve as Divestiture Trustee because of its specialized

knowledge of the therapeutic area and its experience in handling complex corporate partnering and M&A transactions in the Life Sciences sector.

“We are proud of our selection by the FTC and the European Commission to handle this divestiture and of our ability to identify the right company, Schering AG, to develop the global market potential of Refludan,” said Robert C. Rech, a Managing Director of Ferghana Partners Group.

Ferghana Partners is a Life Sciences investment banking group that was formed in 1992 to serve as a worldwide strategic transaction advisor to clients in the pharmaceutical, biotech, specialty chemicals, and diagnostic industries from offices in New York and London.

Ferghana Partners advises clients on corporate development, ownership and business portfolio topics, such as corporate partnering, mergers, acquisitions, joint ventures and divestitures, as well as equity placements.

###